Analysts have been raising their estimates off of the strong quarter, sending the stock to a Zacks #2 Rank (Buy). Based on current consensus estimates, analysts project 16% EPS growth this year and 13% growth next year.
The company also recently raised its dividend by 20%. It currently yields a solid 1.4%.
Pall makes filters. It operates in two segments: Life Sciences and Industrial.
The Life Sciences division is focused on the Medical, BioPharmaceutical and Food & Beverage markets. The Industrial group is focused on the Energy & Water, Aeropower and Microelectronics markets.
It is headquartered in Port Washington, New York and has a market cap of $6.9 billion.
First Quarter Results
Pall delivered better than expected results for the first quarter of its fiscal 2012. Earnings per share came in at 74 cents, beating the Zacks Consensus Estimate by 9 cents. It was a stellar 19% increase over the same quarter in 2011.
Sales jumped 17% year-over-year to a quarterly record of $705.6 million, well ahead of the Zacks Consensus Estimate of $648.0 million. Excluding foreign currency effects, sales rose 12%.
Orders in all three of Pall's global regions grew by double digits, including 15% in Europe. The Life Sciences segment rose 10% in local currencies, driven in large part by a 16% increase in BioPharmaceuticals. The Industrial segment saw top-line growth of 14% as sales to the Energy & Water industries jumped 29%.
Overall gross profit declined from 51.0% to 50.5% of net sales as an increase in Life Sciences was more than offset by a decline in the Industrial group.
Following strong Q1 results, analysts raised their estimates for both 2012 and 2013, sending the stock to a Zacks #2 Rank (Buy).
The Zacks Consensus Estimate for 2012 is now $3.22, representing 16% growth over 2011 EPS. The 2013 consensus estimate is currently $3.65, corresponding with 13% EPS growth.
Analysts believe that a combination of (1) Pall's broad geographic diversification (including an increasing presence in the emerging markets), (2) its steady stream of sales from replacement filters (~75% of revenue), and (3) margin expansion should drive strong double-digit EPS growth over the next several years.
In addition to strong earnings growth, the company pays a dividend that yields a solid 1.4%. On January 19 the company announced a 20% increase in its quarterly dividend to 21 cents per share.
Since 2004, Pall has raised it at a compound annual rate of 11%.
Although it's not a screaming value, valuation is still reasonable for PLL. Shares trade at 17.7x 12-month forward earnings, in-line with the peer group and its 10-year median.
The Bottom Line
With rising estimates, strong growth projections, a solid 1.4% dividend and reasonable valuation, Pall Corporation still offers a lot to like.
This Week's Growth & Income Zacks Rank Buy Stocks:
Omega Healthcare Investors, Inc. (NYSE:OHI - News) offers investors solid growth and exceptionally strong income at a reasonable price. Estimates have been rising after the company delivered better than expected third quarter results. It is a Zacks #2 Rank (Buy). The company also pays a dividend that yields a stellar 7.9%. Valuation is attractive too, with shares trading at less than 11x forward earnings. Read the full article.
Lowe's Companies, Inc. (NYSE:LOW - News) recently laid out an ambitious plan to earn $3.66 per share in 2015, up from ~$1.61 in 2011. The company believes it can get there through solid same-store sales growth, margin expansion, and share buybacks. Analysts have recently been raising their estimates, sending it to a Zacks #2 Rank (Buy). Read the full article.
DSW Inc. (NYSE:DSW - News) raised its guidance for fiscal 2011 on January 10. This prompted analysts to revise their estimates higher too, sending the stock to a Zacks #2 Rank (Buy). DSW has a very solid balance sheet and has been rewarding shareholders through the initiation of a regular quarterly dividend and a $2 per share special dividend. Valuation is attractive too, with shares trading below the industry median. Read the full article.
CVS Caremark Corporation (NYSE:CVS - News) recently raised its guidance for 2012 citing strong profit growth in its pharmacy benefits management business. This prompted analysts to raise their estimates too, sending the stock to a Zacks #2 Rank (Buy) stock. The company also generates strong free cash flow and has been rewarding shareholders through stock buybacks and aggressive dividend hikes. It currently yields a solid 1.5%. Valuation looks reasonable too, with shares trading at just 13.2x forward earnings, below the industry median. Read the full article.
More From Zacks.com